Online Program Home
My Program

Abstract Details

Activity Number: 479 - Complex Innovative Designs in Practice of Early Phase Drug Development
Type: Invited
Date/Time: Wednesday, July 31, 2019 : 10:30 AM to 12:20 PM
Sponsor: Biopharmaceutical Section
Abstract #300207
Title: Phase 1/2 Seamless Design
Author(s): Inna Perevozskaya* and Rosemary Schroyer and Helen Chen
Companies: GSK and GSK and GSK
Keywords: dose-escalation ; oncology ; seamless design; adaptive design ; maximum tolerated dose

Phase I dose-escalation in oncology has seen a dramatic uptake of innovative design usage over the past decade. Many companies are adopting a model-based approach versus traditional 3+3 designs, but even these improved methods cannot dramatically increase precision of MTD finding due to their limited sample size and restrictive dose exploration. There is added on complexity of evaluating multiple drugs (combinations), multiple grades of toxicity or simultaneous assessment of target engagement and toxicity in a single study. In other words, Phase 1 oncology trials of today are very different from small, MTD-focused studies of a single drug with dichotomous endpoint of the past. They are larger, often include substantial expansion cohorts, and their objectives are more complex than simple MTD determination as a single dose to take forward. Such goals are better addressed by incorporating a seamless Phase 2-like extension into initial dose-escalation phase and using combined data along with quantitative decision making to improve the probability of success in further development.

Authors who are presenting talks have a * after their name.

Back to the full JSM 2019 program